GLP-1 Drugs for Men: Testosterone, Muscle, and What Differs From Women

Are GLP-1 results different for men?

Short answer: not substantially for weight loss itself. The STEP and SURMOUNT trials enrolled roughly equal proportions of men and women, and average weight loss outcomes were similar between sexes.

Where sex-specific differences do emerge:

• Starting body composition: Men typically have more lean mass and less overall fat percentage, which affects how weight loss composition looks on DEXA
• Testosterone: Obesity suppresses testosterone; weight loss reverses this — a male-specific positive outcome
• Visceral fat: Men store proportionally more visceral (abdominal) fat, which is metabolically more dangerous and responds particularly well to GLP-1-assisted weight loss
• Cardiovascular outcomes: The SELECT trial (semaglutide 2.4 mg) had approximately 73% male participants, giving strong male-specific cardiovascular outcome data

The testosterone connection

Obesity significantly suppresses testosterone in men through two mechanisms:

1. Aromatase in adipose tissue converts androgens to oestrogens. More fat tissue = more aromatase = lower testosterone
2. Elevated leptin (from adiposity) suppresses hypothalamic GnRH, reducing LH/FSH output and therefore testicular testosterone production

In men with obesity-related hypogonadism (low testosterone from obesity, not primary testicular failure), weight loss — including GLP-1-assisted weight loss — restores testosterone significantly:

• Studies of semaglutide and liraglutide in obese men show testosterone increases of 2–4 nmol/L (roughly 60–120 ng/dL) with significant weight loss
• These increases are roughly proportional to the amount of fat lost, not specific to the GLP-1 drug
• Men who are prescribed testosterone replacement therapy (TRT) for low-T should be aware that weight loss may restore testosterone to normal range, at which point TRT may be discontinued or reduced

What this means practically: Low testosterone is a reversible consequence of obesity in many men. GLP-1 therapy — to the extent it reduces adiposity — is potentially also treating the underlying cause of their low testosterone, not just their weight.

Muscle preservation is a bigger absolute concern for men

While both men and women lose lean mass during GLP-1-assisted weight loss, the absolute concern is somewhat greater for men because:

• Men typically start with more lean mass
• Men's resting metabolic rate is more closely tied to lean mass (women rely more on non-lean-mass metabolic rate)
• Lean mass loss in men is more likely to produce visible and functional consequences at the same percentage loss

The protein and resistance training recommendations apply to all GLP-1 patients, but men should be particularly attentive:

• Protein target: 1.4–1.8 g/kg adjusted body weight (upper end of the range recommended for men, consistent with higher lean mass)
• Resistance training: 3–4 sessions per week of progressive overload training specifically targeting major muscle groups
• Tracking muscle indicators: Grip strength, functional movement capacity, and lean mass via DEXA or InBody at baseline and 6-month intervals

Visceral fat: men's specific advantage

Visceral fat (adipose tissue surrounding abdominal organs) is the metabolically dangerous fat type — associated with insulin resistance, cardiovascular disease, liver disease, and inflammation. Men typically carry a higher proportion of visceral fat than women at equivalent BMI.

GLP-1 drugs appear to be particularly effective at reducing visceral fat:

• Semaglutide STEP trials showed preferential visceral fat reduction relative to subcutaneous fat in obese patients
• Tirzepatide SURMOUNT trials showed similar patterns
• The cardiometabolic benefits of GLP-1 therapy (improved insulin sensitivity, blood pressure, lipids) correlate most strongly with visceral fat reduction

What this means for men: The cardiometabolic benefit of GLP-1 therapy may be somewhat greater per unit of weight lost for men than women, because a higher proportion of the weight lost is the high-risk visceral fat that drives the metabolic harm.

The cardiovascular outcome data for men

The SELECT trial (semaglutide 2.4 mg, cardiovascular outcomes):

• 72.7% of participants were male
• 20% MACE (major adverse cardiovascular events) reduction applied across sex subgroups
• Men-specific HR was approximately 0.81 (95% CI 0.71–0.93), consistent with the overall benefit

For men aged 45–65 with obesity and cardiovascular disease history, semaglutide is now one of the most evidence-based cardiovascular risk reduction therapies available — not just a weight loss drug.

Side effects: do men experience them differently?

Trial data does not show dramatically different side effect rates between men and women for GLP-1 drugs. Some patterns:

• Men may be more likely to under-report GI symptoms (cultural under-reporting tendency)
• Men with obesity are more likely to have concurrent sleep apnoea, which may interact with GI symptoms in terms of sleep disruption
• Food aversions to meat are commonly reported and are not sex-specific

GLP-1 for men: the specific concerns about muscle

Many men in patient communities express concern about "losing muscle on Ozempic." This concern is legitimate but manageable:

The reality: GLP-1 therapy produces weight loss that includes lean mass — approximately 25–38% of total weight lost is lean mass in patients not following resistance training and protein protocols. At 20% total body weight loss, this represents meaningful absolute lean mass reduction.

The mitigation: The research on resistance training + protein combined with GLP-1 therapy shows this lean mass loss ratio can be reduced to 15–20% with appropriate lifestyle modifications. The same protocol recommended in strength sports for cutting cycles applies: high protein, high training volume, adequate calories to support muscle protein synthesis.

The reframe: Losing 20% body weight while retaining muscle mass produces dramatically improved body composition and cardiometabolic health. The concern should not be "will I lose muscle" but "what protocol preserves the most muscle while achieving the therapeutic weight loss."

Summary

GLP-1 drugs are as effective in men as women for weight loss. Men-specific benefits include testosterone restoration (from reduced aromatase activity), preferential visceral fat reduction (which drives cardiometabolic benefit), and strong cardiovascular outcome data (SELECT trial, 73% male). Muscle preservation is a greater absolute concern for men and requires deliberate protein and resistance training protocol. The testosterone benefit is real but specific to obesity-related hypogonadism — not a replacement for addressing primary hypogonadism causes.